Streetbeat News

Price Targets

RPHM

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Reneo Pharmaceuticals (NASDAQ:RPHM) and maintained a $30 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:29 am

TIL

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Instil Bio (NASDAQ:TIL) and maintained a $2 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:27 am

BNTX

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on BioNTech (NASDAQ:BNTX) but has reduced the price target from $180 to $133.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:26 am

EFTR

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and maintained a $5 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:24 am

AZTA

Needham analyst David Saxon has reiterated a Buy rating on Azenta (NASDAQ:AZTA) and maintained a price target of $68.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:21 am

GENI

Needham analyst Bernie McTernan has maintained a Buy rating on Genius Sports (NYSE:GENI) but has reduced the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:19 am

HUBS

Capital One analyst Connor Murphy has initiated coverage on HubSpot (NYSE:HUBS) with an Overweight rating and set a price target of $525 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:18 am

SKIN

Piper Sandler analyst Korinne Wolfmeyer downgraded Beauty Health (NASDAQ:SKIN) from Overweight to Underweight and significantly reduced the price target from $12 to $2, indicating a bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:15 am

SKIN

Canaccord Genuity analyst Susan Anderson downgraded Beauty Health (NASDAQ:SKIN) from Buy to Hold and reduced the price target from $10 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:12 am

RBOT

Canaccord Genuity analyst Caitlin Cronin downgraded Vicarious Surgical (RBOT) from Buy to Hold and significantly reduced the price target from $9 to $0.4, indicating a bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:10 am